These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28562690)

  • 1. Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.
    Kim SH; Park WS; Kim SH; Seo HK; Joung JY; Lee KH; Chung J
    PLoS One; 2017; 12(5):e0177975. PubMed ID: 28562690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
    Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
    Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
    Ng CS; Wang X; Faria SC; Lin E; Charnsangavej C; Tannir NM
    AJR Am J Roentgenol; 2010 Jan; 194(1):166-71. PubMed ID: 20028919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.
    Drljevic-Nielsen A; Donskov F; Mains JR; Andersen MB; Thorup K; Thygesen J; Rasmussen F
    AJR Am J Roentgenol; 2022 May; 218(5):867-876. PubMed ID: 34910540
    [No Abstract]   [Full Text] [Related]  

  • 6. Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.
    Hugonnet F; Fournier L; Medioni J; Smadja C; Hindié E; Huchet V; Itti E; Cuenod CA; Chatellier G; Oudard S; Faraggi M;
    J Nucl Med; 2011 Jul; 52(7):1048-55. PubMed ID: 21680694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CT Intensity Distribution Curve (Histogram) Analysis of Patients Undergoing Antiangiogenic Therapy for Metastatic Renal Cell Carcinoma.
    Boos J; Revah G; Brook OR; Rangaswamy B; Bhatt RS; Brook A; Raptopoulos V
    AJR Am J Roentgenol; 2017 Aug; 209(2):W85-W92. PubMed ID: 28570097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
    Krajewski KM; Franchetti Y; Nishino M; Fay AP; Ramaiya N; Van den Abbeele AD; Choueiri TK
    Oncologist; 2014 May; 19(5):507-14. PubMed ID: 24755461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    Smith AD; Lieber ML; Shah SN
    AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma.
    Wang Y; Cui L; Zhang J; Zhang L; Zhang J; Zhao X; Chen Y
    Abdom Radiol (NY); 2019 Oct; 44(10):3370-3376. PubMed ID: 31399787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computed tomography characteristics of unresectable primary renal cell carcinoma treated with neoadjuvant sunitinib.
    Salem ME; Shah SN; Elson P; Garcia JA; Wood LS; Medsinge A; Campbell S; Dreicer R; Rini BI
    Clin Genitourin Cancer; 2014 Apr; 12(2):117-23. PubMed ID: 24126239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
    Iacovelli R; Lanoy E; Albiges L; Escudier B
    BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
    Krajewski KM; Nishino M; Franchetti Y; Ramaiya NH; Van den Abbeele AD; Choueiri TK
    Cancer; 2014 Mar; 120(5):711-21. PubMed ID: 24264883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of baseline visceral fat accumulation on prognosis in patients with metastatic renal cell carcinoma treated with systemic therapy.
    Mizuno R; Miyajima A; Hibi T; Masuda A; Shinojima T; Kikuchi E; Jinzaki M; Oya M
    Med Oncol; 2017 Apr; 34(4):47. PubMed ID: 28213730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.